| Literature DB >> 18024093 |
Abstract
Biomarkers have shown promising utilities at various stages of the pharmaceutical R & D. With the recent technological advancements and the introduction of protein and gene arrays, high performance instrumentation (e.g., high-field nuclear magnetic resonance and high-resolution mass spectrometers), and bioinformatics, decisions on safety and efficacy criteria can be made with a higher degree of confidence. However, there is a scarcity of robust and valid biomarkers to accelerate the drug development process from pre-clinical through all stages of clinical studies. In this article, a brief overview of current definitions, biomarker categories, challenges in biological and analytical validation, along with several clinical examples will be presented.Mesh:
Substances:
Year: 2007 PMID: 18024093 DOI: 10.1016/j.vascn.2007.10.002
Source DB: PubMed Journal: J Pharmacol Toxicol Methods ISSN: 1056-8719 Impact factor: 1.950